BioCryst Pharmaceuticals | BCRX - Sales Revenues


BioCryst Pharmaceuticals reported $218.25M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Chugai Pharma JPY 341.6B 19.85B Jun/2026
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
DBV Technologies USD 645K 2.13M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novavax USD 147.14M 76.69M Dec/2025
PTC Therapeutics USD 361M 88M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026